research Alopecia With Endocrine Therapies in Patients With Cancer
Endocrine therapies for cancer significantly increase the risk of hair loss.
Search
forLearn
0 / 0 results — no results
Research
5 / 75 results 
research Gender Differences in Skin Aging and the Changing Profile of the Sex Hormones with Age
The document concludes that there are still unknowns about the effectiveness, risks, and detection of performance-enhancing drugs, and doping remains a challenge.
research Remediation of Prostate-Related Disorders Using Polyphenols: Kolaviron and Quercetin in Perspective
Kolaviron and quercetin may help treat prostate issues.
research Rapid Determination of Finasteride in Human Plasma by UPLC-MS/MS and Its Application to Clinical Pharmacokinetic Study
New method measures finasteride in blood quickly and accurately.
research Improvement of General Symptoms in a Chronic Psychotic Patient Treated with Finasteride: Case Report
Finasteride improved symptoms in a schizophrenia patient.
Community Join
5 / 38 resultscommunity Anyone wanna try and interview the developers of RU?
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
community So we’re just ok with taking a research chemical now?
The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.
community Maintaining hair until Breezula without Fin
A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community [Research/Science] What's the General Consensus On RU58841?
User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.